Advertisements

Майфортик

Quick links to important sections

Майфортик

Selected form

Advertisements
Advertisements

Treatment option: Kidney Transplant

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Майфортик

What is Майфортик? Defining the Immunosuppressant Agent

Property Description
Active ingredient Mycophenolic Acid (as Mycophenolate Sodium)
Form Delayed-release tablets (Gastro-resistant)
Pharmacological class Antimetabolite Immunosuppressant
Common use Prevention of organ rejection
Origin Synthetic compound

Майфортик (Myfortic) is a brand-name, prescription-only medication developed by Novartis and classified as an antimetabolite immunosuppressant. Its active pharmaceutical ingredient is Mycophenolic Acid (MPA), supplied as the sodium salt, Mycophenolate Sodium. This classification confirms that the drug's primary function is to intentionally reduce the intensity of the body's immune response, a property clinically recognized for its utility in transplant care. While Mycophenolic Acid was originally derived from fungal sources, the substance used in the final pharmaceutical product is manufactured synthetically to ensure precise quality and consistent concentration.


Composition and Physical Form of Майфортик

The core therapeutic component is the single ingredient, Mycophenolic Acid. Майфортик is notably presented for oral administration as a delayed-release tablet, often referred to as a gastro-resistant or enteric-coated formulation. This is a key distinguishing factor from other mycophenolate compounds. This specialized coating is engineered to remain intact in the stomach's acidic environment, preventing the release of the active compound until the tablet reaches the higher pH of the small intestine. This distinction in design is aimed at ensuring consistent drug delivery and optimizing absorption.


General Purpose: Why is Майфортик Prescribed?

The general purpose of Майфортик is to provide essential prophylaxis against organ rejection in patients who have received an allogeneic transplant, most commonly a kidney. The drug acts by specifically suppressing the growth and multiplication of lymphocytes (T- and B-cells), which are the immune cells primarily responsible for attacking and rejecting a new organ. By limiting the proliferation of these key cells, the medication ensures the sustained acceptance of the donor organ, forming a critical part of the long-term therapeutic regimen.

Advertisements

What side effects are possible with Майфортик?

Possible Side Effects and Safety Information

The official safety profile for Mycophenolate Sodium (Майфортик) is structured around the risks inherent to its function as an immunosuppressant, which increases the susceptibility to infection and the development of malignancies. Adverse reactions are classified by frequency, based on regulatory standards.

Frequency-Classified Adverse Reactions

The most frequently reported effects fall into the Very Common category (affecting more than 1 in 10 patients) and include disorders of the blood and lymphatic system, primarily leukopenia (a reduction in white blood cells), and gastrointestinal disorders, such as diarrhea.

Common adverse reactions (1 to 10 in 100 patients) include anemia, thrombocytopenia, sepsis, and further gastrointestinal issues like abdominal pain and nausea. These effects are categorized across system-organ classes including Infections and Infestations, Blood and Lymphatic System, and Gastrointestinal Disorders.

Serious Safety Considerations

The regulatory labels highlight several serious, potentially life-threatening adverse reactions, including severe opportunistic infections (such as Cytomegalovirus and Progressive Multifocal Leukoencephalopathy or PML) and an elevated risk of developing lymphomas and skin malignancies. Cases of Pure Red Cell Aplasia (PRCA) and serious gastrointestinal complications, such as ulceration and bleeding, are also documented.

Population-Specific Constraints

Mycophenolate is formally classified as a human teratogen. Its use during pregnancy carries a high risk of spontaneous abortion and congenital malformations. Additionally, older adults (aged 65 and over) may have a higher risk of specific infections and gastrointestinal or hematological adverse effects. The risk of leukopenia is often observed more frequently early in treatment or following dose increases.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Any suspected over-exposure to Mycophenolate Sodium (Майфортик) requires immediate attention from emergency medical services. Government regulatory authorities explicitly mandate that individuals must seek immediate medical attention or consult the nearest hospital or poison control center if too many tablets have been taken.

Documented Overdose Profile

The official regulatory documentation typically does not detail specific acute clinical symptoms following a single, large overdosage. Instead, the primary concern of systemic over-exposure is the exaggeration of the drug's effect, leading to serious, life-threatening outcomes.

Risks from excessive exposure are primarily focused on the potential for severe infections, including opportunistic and fatal outcomes, and signs of bone marrow depression, such as leukopenia.

Management and Procedures

Regulatory statements confirm that no specific chemical antidote is known for Mycophenolic Acid overdose. Management procedures described in official labeling focus on reducing systemic exposure and providing supportive care.

Administration of activated charcoal or cholestyramine (or other bile acid sequestrants) is documented to interfere with the enterohepatic circulation of the active moiety, MPA. Furthermore, official information notes that hemodialysis is not expected to remove clinically significant amounts of Mycophenolic Acid due to its high (approximately 98%) plasma protein binding. Hospital monitoring and supportive observation are required following the mandate for urgent care.

Advertisements

Therapeutic Uses of Майфортик

What Майфортик Treats: Main Uses and Benefits

The primary therapeutic role of Майфортик is to support the maintenance of transplanted organ function. This medication is commonly used as an essential part of the regimen for prophylaxis of organ rejection in kidney transplant recipients. It is relevant for easing symptoms linked to organ-specific functional stress and is applied across domains where additional symptomatic support is needed.

The therapeutic benefit is generally associated with managing the risk of acute organ rejection and contributing to the sustained function of the graft. This supportive role is relevant in contexts involving heightened systemic burden and assists with maintaining functional stability.

Key Clinical Contexts and Benefits

This medication is generally used to provide essential prophylaxis against organ rejection, a strategy that supports the patient during difficult episodes by easing distress. The primary goal is to manage the chronic, underlying immune risk and supports the patient during the post-transplant recovery phase. The use of this medicine is considered relevant for managing the chronic immune challenge inherent in transplantation.


Quick Fact: Support for Functional Stability

Майфортик supports the continuous function of the transplanted organ, a benefit that contributes to easing the overall symptom load related to potential organ decline. This is commonly used across conditions presenting with episodic or fluctuating manifestations.

Advertisements

Eligibility and Restrictions for Use

Official Eligibility and Contraindicated Populations

Myfortic (mycophenolate sodium) is strictly contraindicated and must not be used in the following populations, based on official regulatory documents:

Classification Population/Condition
Absolute Contraindication Pregnant women.
Absolute Contraindication Women of childbearing potential (WOCBP) not using highly effective contraception.
Absolute Contraindication Breastfeeding women.
Absolute Contraindication Patients with known hypersensitivity to mycophenolate sodium, mycophenolic acid, mycophenolate mofetil, or any excipients.
Avoidance Patients with a rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT), such as Lesch-Nyhan syndrome.

Restricted or Conditional Use:

  • Pediatric patients under 5 years of age are generally considered a use-not-established group due to insufficient efficacy and safety data.
  • Patients with severe chronic renal impairment (GFR <25 mL cdot min^-1 cdot 1.73 m^-2) require careful monitoring and follow-up.
  • Patients with active serious digestive system disease must be administered the medicine with caution due to increased risks of complications like ulceration and hemorrhage.

Eligibility Requirements for WOCBP: Therapy must not be initiated until a negative pregnancy test is confirmed, and the patient commits to using highly effective contraception before, during, and for six weeks after treatment.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Myfortic (Mycophenolate Sodium) is documented by regulatory authorities, focusing primarily on substances that alter its systemic exposure and those that pose pharmacodynamic risks.


Official Interaction Statements

  • Exposure Reduction by Gastrointestinal Agents: Co-administration of antacids containing magnesium and aluminum hydroxides significantly reduces Mycophenolic Acid (MPA) plasma concentrations. These agents must not be administered simultaneously.
  • Interference with Enterohepatic Recirculation: Agents like Cholestyramine and other bile acid sequestrants interfere with the enterohepatic recirculation of MPA, which may lead to decreased systemic exposure and a potential reduction in therapeutic effect.
  • Pharmacodynamic Competition: The concurrent use of Azathioprine is not recommended due to competition within the purine metabolic pathway.
  • Antibiotics and Phosphate Binders: The co-administration of Sevelamer (a phosphate binder), Rifampin (an antibiotic), and the combination of Norfloxacin and Metronidazole (antibiotics) is not recommended as they may decrease MPA plasma concentrations.
  • Impact on Contraceptives: Myfortic reduces the plasma levels of hormones in oral contraceptives, which could theoretically reduce their effectiveness.
  • Food Timing Constraint: The medication should be taken on an empty stomach due to the documented reduction in Cmax and delay in Tmax when administered with a high-fat meal.

Population-Specific Notes

The medicine is formally avoided in patients with a hereditary deficiency of Hypoxanthine-Guanine Phosphoribosyl-Transferase (HGPRT) on theoretical grounds related to its mechanism.

Advertisements

Mechanism of Action

Selective Inhibition of the IMPDH Enzyme

This mechanism centers on Mycophenolic Acid ( MPA), which is a highly selective, non-competitive inhibitor of the enzyme IMPDH, particularly the Type II isoform found in immune cells. This targeted interaction directly blocks the synthesis of guanosine nucleotides—essential building blocks for DNA and RNA—thereby contributing to the modulation of immune function.

Targeted Cytostasis of Lymphocytes

By creating a profound depletion of guanosine nucleotides, the drug selectively imposes a cytostatic state, arresting the proliferation of T- and B-lymphocytes. Because these specific immune cells are uniquely dependent on the de novo purine pathway for multiplication, this results in a targeted modulation of the cellular and humoral immune response.

Modulation of Immune Cell Migration

Beyond cell growth arrest, the mechanism influences immune function by impairing the proper glycosylation of adhesion molecules on the surface of T-cells and monocytes. This impairment physically limits the cells' ability to adhere to blood vessel walls and migrate into surrounding tissues, reducing the potential for systemic immune cell accumulation in tissues.

Advertisements

Dosage and Administration Information

Official Administration Guidelines for Майфортик

The administration of Майфортик (Mycophenolate Sodium) is strictly defined by standard guidelines to ensure consistent drug delivery for the prophylaxis of organ rejection in kidney transplant recipients.

Instruction Entity Standard Statement
Route of administration Oral administration only.
Dosing schedule The standard adult dose is 1,440 mg total daily dose, divided into two doses of 720 mg each, taken twice daily (BID).
Timing in relation to meals Instructions require a consistent schedule relative to food intake. Certain guidelines suggest an empty stomach (1 hour before or 2 hours after meals); other protocols permit flexibility but mandate consistency.
Age-group administration rules Older Adults (≥ 65 years): No dose adjustment is typically required. Pediatrics: Dosing is based on body surface area (BSA), up to the 720 mg BID maximum.
Special procedural conditions Must be managed by qualified transplant specialists and used in combination with other agents, such as cyclosporine and corticosteroids.

Resulting Procedural Structure

The correct use pattern focuses on maintaining the integrity of the delayed-release tablet and adhering to time-based rules:

  • The dose (720 mg) must be administered twice daily (BID), with doses taken approximately 12 hours apart.
  • The tablet must be swallowed whole and must not be crushed, chewed, or cut.
  • A consistent relationship with food intake must be maintained for each dose.

Connection to the Overall Use Protocol

These instructions establish a precise and mandatory framework for using the medicine, starting with the oral route and the requirement that the unique tablet formulation must remain intact. This structure mandates a consistent 12-hour dosing interval and a fixed daily quantity of 1,440 mg to standardize drug exposure. The protocols specify the specialized setting and co-medications required, ensuring administration occurs strictly within the predefined clinical usage parameters.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Майфортик


Evidence for Use in Kidney Transplant Prophylaxis

Research examined Майфортик for its use in tracking acute rejection in a transplanted kidney. Studies designed to evaluate this included multicenter, randomized controlled trials (RCTs) that compared Майфортик against other established treatment protocols. These trials examined large groups of adult kidney transplant recipients who were receiving the medicine as part of a combination regimen with other immunosuppressants. Researchers monitored important outcomes such as Biopsy-Proven Acute Rejection (BPAR) and rates of graft loss (failure of the transplanted organ).

Findings describe patterns observed in the studies that compared Майфортик to the non-enteric-coated form of mycophenolate. These trials monitored outcomes over short to intermediate periods, and the studies reported measurements of acute rejection and graft loss between the two forms of the medicine in stable patients who were switched. The research does not determine whether an individual will respond similarly to the group patterns observed in these studies.


Evidence for Use in Lupus Nephritis

Майфортик was evaluated in research exploring its use for certain severe forms of Lupus Nephritis, an autoimmune condition that affects the kidneys. The available evidence is often derived from clinical studies and literature reports and sometimes involves data extrapolation from studies conducted with a related mycophenolate compound.

Studies monitored outcomes by examining surrogate endpoints, such as tracking specific biomarkers or measured rates of renal response. The evidence is limited for this indication compared to its use in transplantation, and the findings relied primarily on measuring these surrogate endpoints.


Research Gaps and What Remains Uncertain

The research helps contextualize patterns observed so far, but certain areas of uncertainty remain. Evidence is limited regarding long-term outcomes that extend past the initial two-year period in comparative trials for kidney transplant patients. The follow-up durations were limited in these pivotal studies to establish definitive long-term effects.

Special populations also present research gaps: the clinical impact of higher measured drug exposure in pediatric patients is not fully established, and older adult populations have not been formally studied in dedicated clinical trials.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Майфортик (FAQ)


Q: How long after stopping Myfortic can a man safely father a child?

Official regulatory documents indicate that sexually active men should use effective contraception during treatment and for a period of at least 90 days after stopping the medication. This measure is generally recommended due to the reproductive safety concerns documented in the official prescribing information.


Q: Why must women use two forms of birth control while taking Myfortic?

According to the official product information, this medicine can decrease the plasma (blood) levels of hormones in oral contraceptives, potentially lowering their effectiveness. Because of this interaction, official recommendations suggest consulting with a healthcare provider about the need for an additional, highly effective method, such as a barrier method.


Q: Can taking Myfortic make me feel tired or weak?

Studies and official information indicate that fatigue and asthenia, which is the medical term for unusual physical weakness or lack of energy, are commonly reported side effects. These effects are documented in the medication's official list of adverse reactions.


Q: Is it safe to crush or chew Myfortic tablets?

Official administration guidelines state that the tablets should be swallowed whole and not be crushed, chewed, or cut. This is important to maintain the integrity of the gastro-resistant coating, which is specifically designed to control when the active drug is released in the body.


Q: What is the rationale for limiting sun exposure while on Myfortic?

Regulatory warnings highlight that patients taking immunosuppressants have an elevated risk of developing skin malignancies, which are certain types of skin cancers. Therefore, official sources generally note the importance of precautions, such as avoiding excessive exposure to sunlight and UV light, consistent with minimizing this documented risk.


Q: What is the required schedule for blood monitoring while taking this medicine?

Regulatory guidelines indicate that complete blood counts are typically checked weekly during the first month of treatment, twice monthly for the second and third months, and subsequently with decreasing frequency, for up to the first year.


Q: What is the effect of Myfortic on the body's response to vaccines?

Official product information states that live attenuated vaccines are generally avoided when a patient is receiving this medicine because the drug may decrease the expected immune response. The documentation indicates that studies on the effect of the medicine on the response to other types of vaccines have generally not been performed.


Q: Can I take Myfortic with common over-the-counter painkillers like Tylenol (acetaminophen) or ibuprofen (NSAIDs)?

Official regulatory documents have examined the interaction with acetaminophen and found no documented pharmacokinetic interaction. However, official product information notes that caution is warranted when the medicine is combined with other drugs that have the potential to cause gastrointestinal ulcers or bleeding, a class that may include some common pain relievers.


Q: What types of allergic reactions can occur with Myfortic?

Reports documented in the adverse reaction profile of this medicine include severe hypersensitivity reactions. The specific signs noted include symptoms such as rash, itching, hives, swelling of the face or throat, difficulty breathing, and changes in consciousness.


Q: Can I donate blood or semen while taking Myfortic?

Regulatory guidelines indicate that patients should not donate blood during treatment and for at least six weeks after stopping the medicine. Similarly, male patients should not donate semen during therapy and for 90 days following the discontinuation of the drug.


Q: Are there liquid or suspension forms available for Myfortic?

The specific formulation of Майфортик (mycophenolate sodium) is described in official documents as a delayed-release tablet for oral administration. While a related medicine, mycophenolate mofetil, is available in other forms, in official product documentation, this specific product is consistently presented as a gastro-resistant tablet.


Q: What is the frequency of common side effects like headache or cold/flu symptoms?

According to the regulatory safety profile, headache is classified as a common adverse reaction, meaning it is reported often. Flu-like symptoms are reported as an uncommon adverse reaction.


Q: How quickly is leukopenia (low white blood cell count) reversible after stopping or adjusting the dose?

Official warnings state that blood cell disorders like leukopenia (low white blood cells) have been reported. Regulatory documents note that in reported cases involving blood cell disorders, the conditions were observed to be reversible following a reduction in the dose or cessation of therapy.


Q: Does Myfortic affect my ability to drive or use machinery?

Formal studies specifically examining the effect of the medicine on the ability to drive or use machinery have not been performed. Official warnings note that adverse reactions such as dizziness or drowsiness may occur, and these could potentially affect concentration and motor skills.


Q: Why is Myfortic taken in combination with Cyclosporine?

The use of this medicine in combination with cyclosporine and corticosteroids is indicated in regulatory documents for the prevention of organ rejection following a kidney transplant. The medicine is not typically used alone for this purpose.

Advertisements

How should Майфортик be stored and disposed of?

Official Storage and Disposal Requirements for Myfortic

Myfortic (mycophenolate mofetil) must be stored strictly according to regulatory guidelines to maintain its stability and effectiveness.

Storage Component Official Requirement
Temperature Store at controlled room temperature, typically between 15 C and 30 C (59 F and 86 F). Do not refrigerate.
Protection Keep the tablets in the original container, tightly closed, and protected from moisture.
Handling Keep Myfortic out of the reach of children. Avoid inhaling powder or direct skin contact if a tablet is broken; wash with soap and water if exposure occurs.
Disposal Unused or expired medication must be disposed of following local pharmaceutical waste regulations. Do not dispose of Myfortic in household trash or pour it down a sink or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Майфортик found in:

A-Z Index: